Cingulate Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Cingulate Inc. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $2.31M.
- Cingulate Inc. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $6.43M.
- Cingulate Inc. stock issued during period, value, new issues for the quarter ending 2023-09-30 was $1.62M.
- Cingulate Inc. stock issued during period, value, new issues for the quarter ending 2023-06-30 was $218.80K.
- Cingulate Inc. stock issued during period, value, new issues for fiscal 2024 was $6.43M, a 94.31% increase from fiscal 2023.
- Cingulate Inc. stock issued during period, value, new issues for fiscal 2023 was $3.31M.
- Cingulate Inc. stock issued during period, value, new issues for fiscal 2021 was $20.37M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-03-31 | $2.31M 10-Q · filed 2026-08-13 | |
| 2024-12-31 | $6.43M 10-K · filed 2026-03-18 | |
| 2024-03-31 | $6.43M 10-Q · filed 2025-11-13 | |
| 2023-12-31 | $3.31M 10-K · filed 2024-04-01 | |
| 2023-09-30 | $1.62M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $218.80K 10-Q · filed 2023-11-13 | |
| 2021-12-31 | $20.37M 10-K · filed 2023-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |